VSIG10L2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: VSIG10L2

NCBI ID: G338667

VSIG10L2

Other Name(s): uncharacterized protein LOC338667 | V-set and immunoglobulin domain-containing protein 10-like 2 | V-set and immunoglobulin domain containing 10 like 2 | uncharacterized LOC338667 | V-set and immunoglobulin domain-containing protein 10-like | VSXL2_HUMAN | Uncharacterized protein LOC338667

VSIG10L2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

VSIG10L2 is a protein that has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases. VSIG10L2 is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. VSIG10L2 has been shown to play a role in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

VSIG10L2: Structure and Function

VSIG10L2 is a protein that is characterized by its unique structure and its ability to interact with other proteins. VSIG10L2 is a transmembrane protein that is expressed in the brain and is involved in the regulation of synaptic plasticity. The protein is composed of four transmembrane domains and a cytoplasmic tail.

The first transmembrane domain of VSIG10L2 is a N- terminal domain that is involved in the regulation of synaptic plasticity. This domain is composed of a unique protein that is composed of multiple domains, including a helix, a beta-sheet, and a hypervariable region (HVR). The N-terminal domain of VSIG10L2 is involved in the regulation of synaptic plasticity by interacting with other proteins and modulating the activity of enzymes that are involved in the regulation of synaptic plasticity.

The second transmembrane domain of VSIG10L2 is a C- terminal domain that is involved in the regulation of synaptic plasticity. This domain is composed of a unique protein that is composed of multiple domains, including a helix, a beta-sheet, and a hypervariable region (HVR). The C-terminal domain of VSIG10L2 is involved in the regulation of synaptic plasticity by interacting with other proteins and modulating the activity of enzymes that are involved in the regulation of synaptic plasticity.

The third transmembrane domain of VSIG10L2 is a T- terminal domain that is involved in the regulation of synaptic plasticity. This domain is composed of a unique protein that is composed of multiple domains, including a helix, a beta-sheet, and a hypervariable region (HVR). The T-terminal domain of VSIG10L2 is involved in the regulation of synaptic plasticity by interacting with other proteins and modulating the activity of enzymes that are involved in the regulation of synaptic plasticity.

The fourth transmembrane domain of VSIG10L2 is a cytoplasmic tail that is involved in the regulation of synaptic plasticity. This tail is composed of a unique protein that is composed of multiple domains, including a helix and a hypervariable region (HVR). The cytoplasmic tail of VSIG10L2 is involved in the regulation of synaptic plasticity by interacting with other proteins and modulating the activity of enzymes that are involved in the regulation of synaptic plasticity.

VSIG10L2: Potential Drug Target

VSIG10L2 has been shown to play a role in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The VSIG10L2 protein is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. VSIG10L2 has been shown to interact with other proteins and modulate the activity of enzymes that are involved in the regulation of synaptic plasticity.

VSIG10L2 has the potential to be a drug target or biomarker for the treatment of neurodegenerative diseases. By targeting the VSIG10L2 protein, researchers may be able to develop new treatments for these diseases that specifically target this protein and modulate its activity. This could lead to a more effective and more targeted treatment of neurodegenerative diseases.

VSIG10L2: Biomarker

VSIG10L2 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The VSIG10L2 protein is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. VSIG10L2 may be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases, as its levels can be affected by the underlying condition.

VSIG10L2 has the potential to be a valuable biomarker for the diagnosis and monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The VSIG10L2 protein is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This suggests that VSIG10L2 may be affected by the underlying condition and could be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Conclusion

VSIG10L2 is a protein that has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases. VSIG10L2 is involved in the regulation of synaptic plasticity and has been shown to play a role in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The VSIG10L2 protein is composed of four transmembrane domains and is expressed in the brain. The first three transmembrane domains of VSIG10L2 are involved in the regulation of synaptic plasticity, while the fourth transmembrane domain is involved in the regulation of synaptic plasticity. VSIG10L2 has the potential to be a drug target or biomarker for the treatment of neurodegenerative diseases. The VSIG10L2 protein is also a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Protein Name: V-set And Immunoglobulin Domain Containing 10 Like 2

The "VSIG10L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSIG10L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets